(Source: Alexion Pharmaceuticals Inc) NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that researchers presented new results from the REGAIN study, a global, placebo-controlled Phase 3 registration trial of eculizumab (Soliris) in patients with refractory generalized myasthenia gravis (gMG), at the Hot Topics session of the 14th International Congress on Neuromuscular Diseases (ICNMD) in Toronto. As previously reported, the study's primary efficacy endpoint of change from baseline in Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score, a patient-reported assessment, at week 26, did not reach statistical significance...
↧